Moffitt Cancer Center Administration includes the Research Executive Committee (REX), Scientific Leadership Committee (SLC), and Research Administration. REX establishes the overall scientific direction of the Center through strategic planning investment, evaluation, and nimble, coordinated activities that take advantage of unique opportunities or that address problems. Research Administration operationalizes and supports this vision. REX members include the Center Director and the six Associate Center Directors (ACDs) of Basic, Clinical, Population, and Translational Sciences; Education & Training; and Research Administration. This committee meets weekly for one and a half to two hours. This frequency ensures that activities related to recruitment, research development (including the Grant Review Committee, GRC), planning, space, academic affairs, and policy are rapidly addressed, while fostering a highly collaborative and integrated culture. The REX members are all highly productive scientists and leaders; collectively they have more than 110 years of Cancer Center leadership experience. SLC includes REX plus Program Leaders and Center of Excellence (transdisciplinary interest groups) Leaders. This group advises the Director and REX, with subcommittees for shared resources (Core Leadership Committee, CLC), member evaluation (Membership Committee, MC), clinical science (Clinical Research Action Committee, CRAC), and technology transfer/development (Innovation & Technology Committee, ITC). CCSG Research Administration is composed of 68 (only 2.6 FTE requested) staff members that support Moffitt's 142 Members, 698 other staff, and 13 shared resources. Reporting to the ACD of Research Administration, the administrative unit includes three Senior Directors, five Directors, four Managers, and their teams. Administration assists the Center Director in the ongoing research strategic planning and evaluation process; regular member and staff communications; faculty recruitment; shared resource oversight, including chargebacks, performance review, and user satisfaction; managing the $145 million annual budget, including philanthropic funds; awarding and monitoring more than $2 million in annual institutionally-supported developmental awards; managing and implementing MCC policies for 333,000-sf of dedicated research space; conducting the quarterly membership review and monitoring process; and arranging and documenting approximately 150 Center meetings and retreats per year. The current budget requests for Senior Leadership and Administration are $174,034 (9% of CCSG budget) and $153,888 (8% of CCSG budget), respectively. Collectively this represents less than 0.3% of the overall institutional research budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-21
Application #
9637338
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2019-02-01
Project End
2022-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Bowman-Curci, Meghan; Quinn, Gwendolyn P; Reinecke, Joyce et al. (2018) Comparing fertility preservation resources and policies between NCCN member and non-member institutions. Support Care Cancer :
Hampras, Shalaka S; Locke, Frederick L; Chavez, Julio C et al. (2018) Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 59:911-917
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75

Showing the most recent 10 out of 1254 publications